Medtronic picks up a CE mark for its next-gen pacemaker

Medtronic ($MDT) has launched its latest pacemaker in Europe, picking up CE mark clearance for Viva CRT-P, a device it touts as improving patient response rates. The implant, a cardiac resynchronization therapy pacemaker, is outfitted with Medtronic's AdaptivCRT software, an algorithm-based technology designed to automatically adjust pacing to patients' specific heart function. In clinical trials, the software demonstrated a 21% reduction in heart failure hospitalization and a 46% decline in risk of atrial fibrillation, according to Medtronic. More

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.